Syros Pharmaceuticals Inc.
NASDAQ:SYRS
| Market Cap (Intraday) | 321.61M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $5.81 |
| 50-Day MA | $7.39 |
| 200-Day MA | $9.67 |
Syros Pharmaceuticals Inc. Stock, NASDAQ:SYRS
35 CambridgePark Drive, 4th floor, Cambridge, Massachusetts 02140
United States of America
Phone: +1.617.744.1340
Number of Employees: 103
Description
Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.